Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Andrew Tutt, PhD, MBChB, on Clinical Implications of Treating Metastatic Breast Cancer With Olaparib

Posted: Wednesday, July 14, 2021

Andrew Tutt, PhD, MBChB, of the Institute of Cancer Research, London, discusses key evidence from the OlympiA trial for clinicians treating women with BRCA-mutated and high-risk HER2-negative early breast cancer and how this study may alter the treatment landscape.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.